Clinical trial
ABT-751 With Chemotherapy for Relapsed Pediatric ALL
NCT00439296 · Therapeutic Advances in Childhood Leukemia Consortium, Other · Terminated
Key facts
| NCT number | NCT00439296 |
|---|---|
| Title | ABT-751 With Chemotherapy for Relapsed Pediatric ALL |
| Official title | A Phase I/II Trial of ABT-751 Combined With Dexamethasone, PEG-asparaginase, and Doxorubicin in Relapsed Acute Lymphoblastic Leukemia (ALL) |
| Lead sponsor | Therapeutic Advances in Childhood Leukemia Consortium, Other |
| Collaborators | Abbott Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Pediatric ALL, Relapsed Pediatric ALL, Acute Lymphoblastic Leukemia, Refractory Pediatric ALL |
| Intervention type | Drug |
| Interventions | ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Cyclophosphamide, 6-thioguanine |
| Enrollment | 9 |
| Start date | May 22, 2006 |
| Primary completion | May 19, 2009 |
| Completion | Sep 23, 2009 |
| First posted | Feb 23, 2007 |
| Last update posted | Mar 17, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: